Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

NCT ID: NCT03925935

Last Updated: 2022-03-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-05-07
• Study Completion Date: 2021-11-08

Brief Summary

A phase 1, open label, multi-center trial of AB-205 in adults with Hodgkin or non-Hodgkin lymphoma who are in chemo-sensitive remission undergoing high-dose therapy, with or without radiation, and autologous stem cell transplantation (HDT-ASCT). Subjects will receive AB-205 infusion following autologous stem cell transfusion on Day 0.

Conditions

Hodgkin Lymphoma; Non-hodgkin Lymphoma

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental

Up to 3 sequential dose escalation cohorts of AB-205

Group Type: EXPERIMENTAL

AB-205

Intervention Type: BIOLOGICAL

Engineered human umbilical vein endothelial cells

Interventions

AB-205

Engineered human umbilical vein endothelial cells

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Diagnosis of Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) who are candidates for HDT-ASCT with one of the following conditioning regimens:

• carmustine, etoposide, cytarabine, melphalan (BEAM)
• cyclophosphamide, carmustine, etoposide (CBV)
• thiotepa, busulphan, cyclophosphamide (TBC)
• additional myeloablative chemotherapy-based conditioning regimens may be permitted with the approval of the medical monitor
• Adjunct radiation therapy to HDT will be allowed.
• Adequate organ function is required, defined as follows:

• Serum bilirubin ≤ 2 mg/dL, unless benign congenital hyperbilirubinemia
• AST, ALT, and alkaline phosphatase < 3 times the upper limit of normal
• Creatinine clearance ≥ 40 ml/min (calculated by Cockcroft Gault)
• LVEF ≥ 45% by MUGA or resting echocardiogram
• Pulmonary function (FEV1 and corrected DLCO) ≥ 45% predicted
• Adequate performance status ECOG ≤1
• For female subjects of childbearing potential:

• A negative serum or urine pregnancy test at screening.
• Subject must be willing to use a recommended method of contraception from the start of the screening period and throughout the study period.
• For males who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception:

• Subject must be willing to use a recommended method of contraception and refrain from sperm donation from the start of conditioning therapy for at least 1 year after completion and discussion with a treating physician.
• Willingness and ability to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions.
• Ability to provide written informed consent.

Exclusion Criteria

• History of prior ASCT.
• Active malignancy other than the one for which the subject is undergoing HDT-ASCT. (Subjects with cervical carcinoma in situ or localized basal or squamous cell carcinoma treated with definitive surgery are eligible.)
• Subjects with a serious concomitant medical condition that could interfere with the conduct of the clinical trial, such as unstable angina, renal failure requiring hemodialysis, or active infection requiring IV antibiotics.
• Active Human Immunodeficiency Virus (HIV) infection and Acquired Immunodeficiency Syndrome (AIDS).
• Females who are pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 30 days or longer after chemotherapy treatment discontinuation if required by prescribing information for chemotherapy agents received during the study.
• Subjects who have known hypersensitivity reactions to bovine (cow) proteins or documented allergy to DMSO.
• Subject has other conditions that in the opinion of the investigator would place the subject at increased risk for toxicity by participation in the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

California Institute for Regenerative Medicine (CIRM)

OTHER

Sponsor Role: collaborator

Angiocrine Bioscience

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Paul Finnegan, MD

Role: STUDY_DIRECTOR

Angiocrine Bioscience

Locations

City of Hope Comprehensive Cancer Center

Duarte, California, United States

UC Davis Comprehensive Cancer Center

Sacramento, California, United States

UC San Diego Moores Cancer Center

San Diego, California, United States

The University of California San Francisco

San Francisco, California, United States

University of Michigan

Ann Arbor, Michigan, United States

Hackensack University Medical Center

Hackensack, New Jersey, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, United States

MD Anderson

Houston, Texas, United States

Countries

United States

Other Identifiers

AB-205-001

Identifier Type: -

Identifier Source: org_study_id